Confidential Treatment Requested Under 17 C.F.R. 200.80(b)(4) and 240.24b-2
Exhibit 10.50
| Confidential Treatment Requested |
|
CHANGE ORDER
LETTER OF PAYMENT AUTHORIZATION
14 Nov 2012
Gary Hattersley, Ph.D.
Vice President, Biology
RADIUS HEALTH, INC.
5th Floor
300 Technology Square
Cambridge, MA 02139
United States
| RE: |
| STUDY # 20033374 |
| BLOOD SAMPLE COLLECTION FROM FEMALE NON-HUMAN PRIMATES FOLLOWING A SINGLE SUBCUTANEOUS DOSE OR TRANSDERMAL PATCH DOSE OF BA058 | |||
|
|
| FINAL PROTOCOL AND PROTOCOL AMENDMENT 1 |
|
|
| ||
|
|
| STUDY START: | 09 OCT 2012 |
| STUDY END: | 25 OCT 2012 | |
Dear Dr. Hattersley,
This communication is to serve as a Letter of Payment Authorization (LOPA) for the above referenced study, which will be performed at Charles River Laboratories Preclinical Services as set forth below. Charles River Laboratories Preclinical Services shall perform these services in accordance with the existing Service Agreement executed between Charles River Laboratories Preclinical Services and Radius Health, Inc. Once fully executed, this LOPA shall be incorporated into and made part of the existing Service Agreement.
The payment schedule and price of this Final Protocol and Protocol Amendment Adjustment is as follows:
| · $ [*] | Final Protocol Adjustment on Study |
|
|
|
| · $ [*] | Protocol Amendment 1 Adjustment on Study |
|
|
|
| · $ [*] | Total Cost |
|
|
|
| · $ 11,856 | Total Cost with [*]% discount — Due upon adjustment billing |
Total study cost: $82,344
Final Protocol adjustment due to:
· Increased number of blood sample collections and processing
Protocol Amendment 1 adjustment due to:
· An additional dose day was added to the study design
· Increased number of blood sample collections and processing
· Additional dose site observations added
In the event the study design is altered, or the study is postponed or cancelled, payments will be amended as follows:
The price impact (if any) of the protocol amendment/change order will be submitted in writing. If study prices increase the difference will be invoiced and payable upon acceptance by the Sponsor. If study prices decrease, the Sponsor will be credited for the difference.
Charles River, 6995 Longley Lane, Reno, NV 89511
[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
Form No. LC-08-F04 Revised 05-18-06
As acceptance of this agreement, please sign this Letter of Payment Authorization and return to me at the letterhead address or fax to me at ###-###-####. Should you have any questions, please call me at ###-###-####.
| /s/ Gary Hattersley |
| /s/ Danielle M. Florey |
| Authorized Sponsor Representative |
| Danielle M. Florey |
|
|
| Client Manager, Client Services |
| Gary Hattersley, SVP Preclinical Development |
| 14 Nov 2012 |
| Print (Name and Title) |
|
|
|
|
|
|
| November 15, 2012 |
|
|
| Date |
|
|
[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
Charles River, 6995 Longley Lane, Reno, NV 89511
2
